Pharmacological management of women with mixed urinary incontinence

Drugs

Volumn 66, Issue 5, 2006, Pages 591-606

  Hashim, Hashim ^a   Abrams, Paul ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLENBUTEROL; DARIFENACIN; DESMOPORESSIN; DIURETIC AGENT; DULOXETINE; EPHEDRINE; ESTROGEN; FESOTERODINE; IMIPRAMINE; METHOXAMINE; MIDODRINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NOREPHEDRINE; OXYBUTYNIN; PROPIVERINE; PROPRANOLOL DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SOLIFENACIN; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; VASOPRESSIN DERIVATIVE;

BLEEDING; BLURRED VISION; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; CYSTOMETRY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENTIATION; FATIGUE; FLUID RETENTION; HEADACHE; HEART DISEASE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPONATREMIA; INSOMNIA; LIFESTYLE; LUNG DISEASE; META ANALYSIS; MIXED INCONTINENCE; NAUSEA; ORTHOSTATIC HYPOTENSION; PATIENT EDUCATION; PELVIC FLOOR MUSCLE TRAINING; PREVALENCE; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STRESS INCONTINENCE; SURGICAL INFECTION; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT FAILURE; TREMOR; URINARY URGENCY; URODYNAMICS; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC AGENTS; ANTIDIURETIC AGENTS; BIOFEEDBACK (PSYCHOLOGY); COST OF ILLNESS; FEMALE; HUMANS; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; URINARY INCONTINENCE;

EID: 33646359437     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666050-00002     Document Type: Review

References (89)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21 (2): 167-78
2. Hunskaar S, Burgio K, Clark A, et al. Epidemiology of urinary (UI) and faecal (FI) incontinence and pelvic organ prolapse (POP). In: Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence. Paris: Health Publication Ltd, 2005: 255-312
3. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 May; 20 (6): 327-36
4. Hannestad YS, Rortveit G, Sandvik H, et al. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol 2000 Nov; 53 (11): 1150-7
5. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006 Jan; 175 (1): 191-5
6. Brading AF. A myogenic basis for the overactive bladder. Urology 1997 Dec; 50 (6A Suppl.): 57-67
7. de Groat WC. A neurologic basis for the overactive bladder. Urology 1997 Dec; 50 (6A Suppl.): 36-52
8. Mostwin J, Bourcier A, Haab F, et al. Pathophysiology of urinary incontinence, fecal incontinence and pelvic organ prolapse. In: Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence. Paris: Health Publication Ltd, 2005: 423-84
9. Rortveit G, Daltveit AK, Hannestad YS, et al. Vaginal delivery parameters and urinary incontinence: the Norwegian EPIN-CONT study. Am J Obstet Gynecol 2003 Nov; 189 (5): 1268-74
10. Mostwin JL. Pathophysiology: the varieties of bladder overactivity. Urology 2002 Nov; 60 (5 Suppl. 1): 22-6
11. Takazawa K, Arisawa K. Relationship between the type of urinary incontinence and falls among frail elderly women in Japan. J Med Invest 2005 Aug; 52 (3-4): 165-71
12. Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. Obstet Gynecol 2001 Sep; 98 (3): 398-406
13. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004 Mar; 63 (3): 461-5
14. Turner DA, Shaw C, McGrother CW, et al. The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int 2004 Jun; 93 (9): 1246-52
15. Coyne KS, Zhou Z, Thompson C, et al. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003 Nov; 92 (7): 731-5
16. Monz B, Pons ME, Hampel C, et al. Patient-reported impact of urinary incontinence-Results from treatment seeking women in 14 European countries. Maturitas 2005 Nov; 52 Suppl. 2: 24-34
17. Yip SK, Chan A, Pang S, et al. The impact of urodynamic stress incontinence and detrusor overactivity on marital relationship and sexual function. Am J Obstet Gynecol 2003 May; 188 (5): 1244-8
18. Abrams P, Andersson KE, Brubaker L, et al. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence. Paris: Health Publication Ltd, 2005: 1589-630
19. Bent AE, Gousse AE, Hendrix SL, et al. Validation of a two-item quantitative questionnaire for the triage of women with urinary incontinence. Obstet Gynecol 2005 Oct; 106 (4): 767-73
20. Steele AC, Kohli N, Mallipeddi P, et al. Pharmacologic causes of female incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10 (2): 106-10
21. Bump RC, McClish DK. Cigarette smoking and urinary incontinence in women. Am J Obstet Gynecol 1992; 167: 1213-8
22. Bump RC, McClish DK. Cigarette smoking and pure genuine stress incontinence of urine: a comparison of risk factors and determinants between smokers and nonsmokers. Am J Obstet Gynecol 1994 Feb; 170: 579-82
23. Mushkat Y, Bukovsky I, Langer R. Female urinary stress incontinence: does it have familial prevalence? Am J Obstet Gynecol 1996 Feb; 174 (2): 617-9
24. Bai SW, Kang JY, Rha KH, et al. Relationship of urodynamic parameters and obesity in women with stress urinary incontinence. J Reprod Med 2002 Jul; 47 (7): 559-63
25. Bump RC, Mattiasson A, Bo K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 1996 Jul; 175 (1): 10-7
26. Staskin D, Hilton P, Emmanuel A, et al. Initial assessment of incontinence. In: Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence. Paris: Health Publication Ltd, 2005:
27. Schick E, Jolivet-Tremblay M, Dupont C, et al. Frequency-volume chart: the minimum number of days required to obtain reliable results. Neurourol Urodyn 2003; 22 (2): 92-6
28. Avery K, Donovan J, Peters TJ, et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004; 23 (4): 322-30
29. Abrams P, Blaivas JG, Stanton SL, et al. The standardisation of terminology of lower urinary tract function. The International Continence Society Committee on Standardisation of Terminology. Scand J Urol Nephrol Suppl 1988; 114: 5-19
30. Hannestad YS, Rortveit G, Daltveit AK, et al. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG 2003 Mar; 110 (3): 247-54
31. Subak LL, Whitcomb E, Shen H, et al. Weight loss: a novel and effective treatment for urinary incontinence. J Urol 2005 Jul; 174 (1): 190-5
32. Bo K, Borgen JS. Prevalence of stress and urge urinary incontinence in elite athletes and controls. Med Sci Sports Exerc 2001 Nov; 33 (11): 1797-802
33. Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. J Urol 2005 Jul; 174 (1): 187-9
34. Dallosso HM, McGrother CW, Matthews RJ, et al. Nutrient composition of the diet and the development of overactive bladder: a longitudinal study in women. Neurourol Urodyn 2004; 23 (3): 204-10
35. Dallosso HM, McGrother CW, Matthews RJ, et al. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int 2003 Jul; 92 (1): 69-77
36. Hisayama T, Shinkai M, Takayanagi I, et al. Mechanism of action of nicotine in isolated urinary bladder of guinea-pig: involvement of tachykinin(s) released by nicotine in the drug's sympathomimetic effect. Arch Int Pharmacodyn Ther 1989 Sep; 301: 277-84
37. Koley B, Koley J, Saha JK. The effects of nicotine on spontaneous contractions of cat urinary bladder in situ. Br J Pharmacol 1984 Oct; 83 (2): 347-55
38. Wilson PD, Berghmans B, Hagen S, et al. Adult conservative management. In: Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence. Paris: Health Publication Ltd, 2005: 855-964
39. Millard RJ. Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen. Neurourol Urodyn 2004; 23 (1): 48-53
40. Nygaard IE, Kreder KJ, Lepic MM, et al. Efficacy of pelvic floor muscle exercises in women with stress, urge, and mixed urinary incontinence. Am J Obstet Gynecol 1996 Jan; 174 (1 Pt 1): 120-5
41. Publicover C, Bear M. The effect of bladder training on urinary incontinence in community-dwelling older women. J Wound Ostomy Continence Nurs 1997 Nov; 24 (6): 319-24
42. Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2000; (2): CD001308
43. Yoon HS, Song HH, Ro YJ. A comparison of effectiveness of bladder training and pelvic muscle exercise on female urinary incontinence. Int J Nurs Stud 2003 Jan; 40 (1): 45-50
44. Burgio KL, Robinson JC, Engel BT. The role of biofeedback in Kegel exercise training for stress urinary incontinence. Am J Obstet Gynecol 1986 Jan; 154 (1): 58-64
45. Bo K, Talseth T, Holme I. Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women. BMJ 1999 Feb; 318 (7182): 487-93
46. Alhasso A, Glazener C, Pickard R, et al. Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev 2005; (3): CD001842
47. Weil EH, Eerdmans PH, Dijkman GA, et al. Randomized double-blind placebo-controlled multicenter evaluation of efficacy and dose finding of midodrine hydrochloride in women with mild to moderate stress urinary incontinence: a phase II study. Int Urogynecol J Pelvic Floor Dysfunct 1998; 9 (3): 145-50
48. Ishiko O, Ushiroyama T, Saji F, et al. beta(2)-adrenergic agonists and pelvic floor exercises for female stress incontinence. Int J Gynaecol Obstet 2000 Oct; 71 (1): 39-44
49. Gruneberger A. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. Br J Obstet Gynaecol 1984 Mar; 91 (3): 275-8
50. Hunsballe JM, Djurhuus JC. Clinical options for imipramine in the management of urinary incontinence. Urol Res 2001 Apr; 29 (2): 118-25
51. Lin HH, Sheu BC, Lo MC, et al. Comparison of treatment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynaecol 1999 Oct; 106 (10): 1089-92
52. Thor KB. Targeting serotonin and norepinephrine receptors in stress urinary incontinence. Int J Gynaecol Obstet 2004 Jul; 86 Suppl. 1: S38-52
53. Michel MC, Peters SL. Role of serotonin and noradrenaline in stress urinary incontinence. BJU Int 2004 Jul; 94 Suppl. 1: 23-30
54. Thor KB. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology 2003 Oct; 62 (4 Suppl. 1): 3-9
55. Mariappan P, Ballantyne Z, N'dow J, et al. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database Syst Rev 2005; (3): CD004742
56. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003 Oct; 170 (4 Pt 1): 1259-63
57. Millard RJ, Moore K, Rencken R, et al. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004 Feb; 93 (3): 311-8
58. Norton PA, Zinner NR, Yalcin I, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002 Jul; 187 (1): 40-8
59. Van KP, Abrams P, Lange R, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004 Mar; 111 (3): 249-57
60. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003 Jul; 189 (1): 98-101
61. Bump R, Yalcin I, Voss S. The effect of duloxetine dose escalation and tapering on the incidence of adverse events (AE) in women with stress urinary incontinence (SUI) [abstract no. 116]. Neurourol Urodyn 2005 Sep; 24 (5/6): 582-3
62. Burt VK, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics 2005 Jul; 46 (4): 345-54
63. Ghoniem GM, Van Leeuwen JS, Elser DM, et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 2005 May; 173 (5): 1647-53
64. Bump RC, Norton PA, Zinner NR, et al. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. Obstet Gynecol 2003 Jul; 102 (1): 76-83
65. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004; 64 (15): 1643-56
66. Sellers DJ, Yamanishi T, Chapple CR, et al. M3 muscarinic receptors but not M2 mediate contraction of the porcine detrusor muscle in vitro. J Auton Pharmacol 2000 Jun; 20 (3): 171-6
67. Andersson KE, Appell R, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. Paris: Health Publication Ltd, 2005: 809-54
68. Khullar V, Hill S, Laval KU, et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 2004 Aug; 64 (2): 269-74
69. Abrams P, Avery K, Gardener N, et al. ICIQ Advisory Board. The International Consultation on Incontinence modular questionnaire: www.iciq.net. J Urol 2006 Mar; 175 (3 Pt 1): 1063-6; discussion 1066
70. Kreder KJ, Brubaker L, Mainprize T. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. BJU Int 2003 Sep; 92 (4): 418-21
71. Karram MM, Bhatia NN. Management of coexistent stress and urge urinary incontinence. Obstet Gynecol 1989 Jan; 73 (1): 4-7
72. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 Aug; 168 (2): 580-6
73. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003 Aug; 62 (2): 237-42
74. Kelleher C, Cardozo L, Kobashi K, et al. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunt 2005 Nov; 8: 1-7
75. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev 2003; (2): CD001405
76. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis: First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994 Jan; 83 (1): 12-8
77. Cardozo L, Lose G, McClish D, et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand 2004 Oct; 83 (10): 892-7
78. Robinson D, Cardozo L. Oestrogens and the lower urinary tract. BJOG 2004 Dec; 111 Suppl. 1: 10-4
79. Robinson D, Cardozo L, Akeson M, et al. Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int 2004 May; 93 (7): 996-1000
80. Dwyer PL. Differentiating stress urinary incontinence from urge urinary incontinence. Int J Gynaecol Obstet 2004 Jul; 86 Suppl. 1: S17-24
81. Balmforth J, Cardozo LD. Trends toward less invasive treatment of female stress urinary incontinence. Urology 2003 Oct; 62 (4 Suppl. 1): 52-60
82. Colombo M, Zanetta G, Vitobello D, et al. The Burch colposus-pension for women with and without detrusor overactivity. Br J Obstet Gynaecol 1996 Mar; 103 (3): 255-60
83. Osman T. Stress incontinence surgery for patients presenting with mixed incontinence and a normal cystometrogram. BJU Int 2003 Dec; 92 (9): 964-8
84. Segal JL, Vassallo B, Kleeman S, et al. Prevalence of persistent and de novo overactive bladder symptoms after the tension-free vaginal tape. Obstet Gynecol 2004 Dec; 104 (6): 1263-9
85. Rezapour M, Ulmsten U. Tension-free vaginal tape (TVT) in women with mixed urinary incontinence: a long-term follow-up. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12 Suppl. 2: S15-18
86. Scotti RJ, Angell G, Flora R, et al. Antecedent history as a predictor of surgical cure of urgency symptoms in mixed incontinence. Obstet Gynecol 1998 Jan; 91 (1): 51-4
87. Holmgren C, Nilsson S, Lanner L, et al. Long-term results with tension-free vaginal tape on mixed and stress urinary incontinence. Obstet Gynecol 2005 Jul; 106 (1): 38-43
88. Sand PK, Hill RC, Ostergard DR. Incontinence history as a predictor of detrusor stability. Obstet Gynecol 1988 Feb; 71 (2): 257-60
89. Weidner AC, Myers ER, Visco AG, et al. Which women with stress incontinence require urodynamic evaluation? Am J Obstet Gynecol 2001 Jan; 184 (2): 20-7